Recursion Pharmaceuticals, a biotech firm which uses artificial intelligence to discover new drug candidates to acquire Exscientia, a technology-driven drug design and development company, for $688m. “We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers. Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech-enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started," Chris Gibson, Recursion Co-Founder and CEO.